[go: up one dir, main page]

BRPI0406674A - Composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de um aditivo farmaceuticamente aceitável, método para o tratamento ou prevenção de dor aguda ou crÈnica, dispositivo para pulverização, e, processo para preparar uma composição - Google Patents

Composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de um aditivo farmaceuticamente aceitável, método para o tratamento ou prevenção de dor aguda ou crÈnica, dispositivo para pulverização, e, processo para preparar uma composição

Info

Publication number
BRPI0406674A
BRPI0406674A BR0406674-0A BRPI0406674A BRPI0406674A BR PI0406674 A BRPI0406674 A BR PI0406674A BR PI0406674 A BRPI0406674 A BR PI0406674A BR PI0406674 A BRPI0406674 A BR PI0406674A
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
fentanyl
composition
acceptable salt
acute
Prior art date
Application number
BR0406674-0A
Other languages
English (en)
Inventor
Jonathan David Castile
Peter James Watts
William Columbus Ian Lafferty
Alan Smith
Original Assignee
Archimedes Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9950919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0406674(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Archimedes Dev Ltd filed Critical Archimedes Dev Ltd
Publication of BRPI0406674A publication Critical patent/BRPI0406674A/pt
Publication of BRPI0406674B1 publication Critical patent/BRPI0406674B1/pt
Publication of BRPI0406674B8 publication Critical patent/BRPI0406674B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

"COMPOSIçãO PARA A MINISTRAçãO INTRANASAL DE FENTANILA OU UM SEU SAL FARMACEUTICAMENTE ACEITáVEL, USO DE UM ADITIVO FARMACEUTICAMENTE ACEITáVEL MéTODO PARA O TRATAMENTO OU PREVENçãO DE DOR AGUDA OU CRÈNICA, DISPOSITIVO PARA PULVERIZAçãO, E, PROCESSO PARA PREPARAR UMA COMPOSIçãO". Esta invenção fornece uma composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável a um animal, que compreende uma solução aquosa de (i) fentanila ou um seu sal farmaceuticamente aceitável e (ii) um aditivo farmaceuticamente aceitável, selecionado de (a) uma pectina e (b) um poloxâmero e quitosano ou um sal ou seu derivado; desde que, quando a composição compreender uma pectina, ela é substancialmente livre de íons metálicos divalentes; e que, em comparação com uma simples solução aquosa de fentanila, administrada intranasalmente na mesma dose, provê uma concentração pico de plasma de fentanila (C~ máx~), que é de 10 a 80% daquele obtido utilizando-se uma simples solução aquosa de fentanila, administrada intranasalmente em uma dose idêntica de fentanila.
BRPI0406674A 2003-01-10 2004-01-12 composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição BRPI0406674B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0300531.1A GB0300531D0 (en) 2003-01-10 2003-01-10 Pharmaceutical compositions
PCT/GB2004/000057 WO2004062561A2 (en) 2003-01-10 2004-01-12 Pharmaceutical compositions comprising fentanyl for intranasal delivery

Publications (3)

Publication Number Publication Date
BRPI0406674A true BRPI0406674A (pt) 2005-12-20
BRPI0406674B1 BRPI0406674B1 (pt) 2015-12-22
BRPI0406674B8 BRPI0406674B8 (pt) 2021-05-25

Family

ID=9950919

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406674A BRPI0406674B8 (pt) 2003-01-10 2004-01-12 composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição

Country Status (25)

Country Link
US (5) US20040166067A1 (pt)
EP (2) EP1635783B1 (pt)
JP (1) JP4827725B2 (pt)
KR (3) KR101012148B1 (pt)
CN (1) CN100423709C (pt)
AU (1) AU2004204381B2 (pt)
BR (1) BRPI0406674B8 (pt)
CA (1) CA2511974C (pt)
CY (1) CY1115056T1 (pt)
DK (1) DK1635783T5 (pt)
EA (1) EA008500B1 (pt)
ES (2) ES2432119T3 (pt)
FR (1) FR14C0020I1 (pt)
GB (1) GB0300531D0 (pt)
GE (1) GEP20084340B (pt)
IL (1) IL169480A (pt)
MX (1) MXPA05007333A (pt)
NO (1) NO335127B1 (pt)
NZ (1) NZ541018A (pt)
PL (1) PL212950B1 (pt)
PT (2) PT1635783E (pt)
SI (1) SI1635783T1 (pt)
UA (1) UA85050C2 (pt)
WO (1) WO2004062561A2 (pt)
ZA (1) ZA200505274B (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1307194E (pt) 2000-07-31 2008-05-27 Nycomed Danmark Aps Composição à base de fentanil para administração nasal
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20050129679A1 (en) 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
EP2057982A1 (en) * 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
CZ302789B6 (cs) 2009-11-25 2011-11-09 Zentiva, K. S. Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
KR20140017547A (ko) 2011-02-04 2014-02-11 아르키메데스 디벨로프먼트 리미티드 개량된 용기
SG194927A1 (en) 2011-05-13 2013-12-30 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
ES2748632T3 (es) 2012-10-03 2020-03-17 Proponent Biotech Gmbh Composición farmacéutica que comprende ácido propiónico para uso en el tratamiento de infecciones víricas
KR102321172B1 (ko) 2013-09-05 2021-11-05 에이비2 바이오 에스에이 염증성 질환에서 il-18 결합 단백질(ｉｌ-18ｂｐ)
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
MX2017010919A (es) 2015-03-05 2017-12-07 Ab2 Bio Sa Proteina de union il-18 (il-18bp) y anticuerpos en enfermedades inflamatorias.
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
ES2968153T3 (es) * 2017-01-11 2024-05-08 Torrent Pharmaceuticals Ltd Composición nasal de tapentadol
US11207309B2 (en) 2019-07-19 2021-12-28 Hikma Pharmaceuticals International Limited Ready-to-administer fentanyl formulations
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
CN111272860B (zh) 2020-03-16 2022-11-25 中国检验检疫科学研究院 一种芬太尼类物质的小型便携式质谱现场快速检测方法
EP4146174A1 (en) 2020-05-06 2023-03-15 AB2 Bio SA Il-18 binding protein (il-18bp) in respiratory diseases
GB202007404D0 (en) 2020-05-19 2020-07-01 Nasser Syed Muhammad Tahir Treatment for viral respiratory infections
EP3943097A1 (en) 2020-07-24 2022-01-26 AB2 Bio SA Car-t cell therapy
WO2023067348A1 (en) 2021-10-21 2023-04-27 Biosirius Ltd Treatment for virally-induced pneumonia
EP4486367A1 (en) 2022-03-04 2025-01-08 AB2 Bio SA Il-18 binding protein (il-18bp) in the treatment of vexas

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2125212A (en) 1938-05-03 1938-07-26 Vick Chemical Company Therapeutic composition
US2730483A (en) 1952-08-12 1956-01-10 Nepera Chemical Co Inc Therapeutic compositions comprising neomycin, gramicidin and quaternary ammonium salt of thonzylamine
NL135583C (pt) * 1961-10-10
US3184600A (en) 1963-05-07 1965-05-18 Potter Instrument Co Inc Photosensitive apparatus for measuring coordinate distances
JPS5885813A (ja) 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4659696A (en) 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5122127A (en) 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
HU193780B (en) 1985-06-21 1987-11-30 Richter Gedeon Vegyeszet Process for producing 2-halogeno-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JPS62123112A (ja) 1985-11-22 1987-06-04 Sunstar Inc 軟膏基剤
DE3601132A1 (de) 1986-01-16 1987-07-23 Christian Bannert Verfahren zur behandlung der schleimhaut
JPS62236862A (ja) 1986-04-09 1987-10-16 Nippon Kayaku Co Ltd 人工粘液
ZA875317B (en) 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
ES2042527T3 (es) 1986-11-14 1993-12-16 Theratech Inc Un metodo para preparar una composicion farmaceutica aumentadora de la penetracion para la aplicacion topica.
US4826683A (en) 1987-01-09 1989-05-02 Bates Harry L Decongestant
US5200180A (en) 1987-06-26 1993-04-06 Christian Bannert Pharmaceutical composition for the treatment of the human eye
DE3726797A1 (de) 1987-08-12 1989-02-23 Bayer Ag Arzneimittel fuer den bereich der mundhoehle
US4915948A (en) 1987-08-31 1990-04-10 Warner-Lambert Company Tablets having improved bioadhesion to mucous membranes
US5457093A (en) 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
DE3827561C1 (pt) 1988-08-13 1989-12-28 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5236714A (en) 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
GB8904370D0 (en) 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
JP2911496B2 (ja) 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
GB2237510B (en) 1989-11-04 1993-09-15 Danbiosyst Uk Small particle drug compositions for nasal administration
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5397771A (en) 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
US5346703A (en) * 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
EP0491076A1 (en) 1990-12-19 1992-06-24 Theratech, Inc. Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols
JPH0597706A (ja) 1991-04-09 1993-04-20 Chemex Block Drug Jv アフタ性潰瘍および他の粘膜皮膚障害の処置方法
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
GB9202464D0 (en) 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
EP0571671B1 (en) 1992-05-26 1997-09-17 The Procter & Gamble Company A Pharmaceutical composition in powder form
WO1994002119A1 (fr) 1992-07-23 1994-02-03 Hisamitsu Pharmaceutical Co., Inc. Composition de base administrable par injection percutanee et composition de medicament derivee
WO1994010987A1 (en) 1992-11-09 1994-05-26 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5507277A (en) * 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
DK0689438T3 (da) 1993-03-26 2003-09-29 Franciscus Wilhelmus He Merkus Farmaceutiske præparater til intranasal administration af apomorfin
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
SE9301877D0 (sv) 1993-06-02 1993-06-02 Kabi Pharmacia Ab In situ gel for therapeutic use
CA2167081A1 (en) 1993-07-12 1995-01-26 Alexander K. Andrianov Hydrogel microencapsulated vaccines
US5422116A (en) 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9406171D0 (en) * 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
WO1995026715A2 (en) 1994-03-30 1995-10-12 Dumex-Alpharma A/S Use of fatty acid esters as bioadhesive substances
JP3483148B2 (ja) 1994-04-21 2004-01-06 久光製薬株式会社 経皮投与基剤組成物およびその薬剤組成物
CA2189351C (en) * 1994-05-13 2008-12-30 Stephen J. Farr Narcotic containing aerosol formulation
GB9414966D0 (en) 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
FR2733420B1 (fr) 1995-04-28 1997-06-27 Sep Tarral Preparations pectiques utilisables comme support de medicament
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
PT836511E (pt) 1995-06-05 2004-08-31 Alza Corp Dispositivo para distribuicao de fentanilo e sufentanilo por electrotransporte percutaneo
ZA964320B (en) 1995-06-05 1997-01-13 Alza Corp Device for transdermal electrotransport delivery of fentanyl and sufentanil
JP3098401B2 (ja) 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
DE19527411A1 (de) * 1995-07-27 1997-01-30 Ackermann & Schmitt Gmbh & Co Kupplung
US5840731A (en) 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
EP1024833A1 (en) 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US6667279B1 (en) 1996-11-13 2003-12-23 Wallace, Inc. Method and composition for forming water impermeable barrier
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
GB2328443B (en) 1997-08-21 2001-09-05 Reckitt & Colmann Prod Ltd In situ formation of pharmaceutically acceptable polymeric material
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
CA2312839C (en) 1997-12-02 2008-01-15 Lisbeth Illum Compositions for nasal administration
US6090368A (en) 1998-03-03 2000-07-18 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Pharmaceutical compositions for intranasal spray administration of ketorolac tromethamine
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
CA2341732C (en) 1998-08-26 2008-08-19 Teijin Limited Powder composition for nasal administration
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
JP2000229859A (ja) 1999-02-12 2000-08-22 Teijin Ltd 安定なブプレノルフィン経鼻製剤
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
JP2001002589A (ja) 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
CA2381860C (en) * 1999-08-26 2009-11-24 Takeda Chemical Industries, Ltd. Matrix adhering to nasal mucosa
JP2001089359A (ja) 1999-09-24 2001-04-03 Toko Yakuhin Kogyo Kk 鎮痛成分の点鼻用ゲルまたはゾル製剤
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
JP4969009B2 (ja) 2000-03-10 2012-07-04 ダレクト コーポレーション オピオイド製剤
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
EP1296649A2 (en) 2000-06-22 2003-04-02 Pharmasol Limited Pharmaceutical compositions comprising an opioid analgesic
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
PT1307194E (pt) * 2000-07-31 2008-05-27 Nycomed Danmark Aps Composição à base de fentanil para administração nasal
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
GB2378383A (en) 2001-06-06 2003-02-12 Gursharan Moonga Nasal delivery of pharmaceutical compositions in powder form
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
ES2721899T3 (es) 2019-08-06
US20120277267A1 (en) 2012-11-01
BRPI0406674B1 (pt) 2015-12-22
JP2006516272A (ja) 2006-06-29
EA200501105A1 (ru) 2005-12-29
AU2004204381B2 (en) 2010-11-25
NZ541018A (en) 2008-07-31
CA2511974A1 (en) 2004-07-29
KR20100118144A (ko) 2010-11-04
BRPI0406674B8 (pt) 2021-05-25
CN100423709C (zh) 2008-10-08
US8889176B2 (en) 2014-11-18
EP2436375A1 (en) 2012-04-04
US8216604B2 (en) 2012-07-10
KR20090058596A (ko) 2009-06-09
US9078814B2 (en) 2015-07-14
UA85050C2 (ru) 2008-12-25
HK1088555A1 (en) 2006-11-10
ES2432119T3 (es) 2013-11-29
KR20050103275A (ko) 2005-10-28
WO2004062561A3 (en) 2004-10-07
PL212950B1 (pl) 2012-12-31
EP1635783B1 (en) 2013-09-18
MXPA05007333A (es) 2006-02-17
GB0300531D0 (en) 2003-02-12
CA2511974C (en) 2011-03-01
US20040166067A1 (en) 2004-08-26
CN1723012A (zh) 2006-01-18
ZA200505274B (en) 2014-09-25
DK1635783T5 (da) 2014-05-12
CY1115056T1 (el) 2016-12-14
WO2004062561A2 (en) 2004-07-29
GEP20084340B (en) 2008-03-25
EP2436375B1 (en) 2019-02-27
NO20053119D0 (no) 2005-06-24
SI1635783T1 (sl) 2013-11-29
JP4827725B2 (ja) 2011-11-30
IL169480A (en) 2013-10-31
NO335127B1 (no) 2014-09-22
EA008500B1 (ru) 2007-06-29
DK1635783T3 (da) 2013-10-14
AU2004204381A2 (en) 2004-07-29
AU2004204381A1 (en) 2004-07-29
KR101012148B1 (ko) 2011-02-07
NO20053119L (no) 2005-08-03
PT1635783E (pt) 2013-10-29
PL377823A1 (pl) 2006-02-20
US9814705B2 (en) 2017-11-14
IL169480A0 (en) 2007-07-04
FR14C0020I1 (fr) 2014-04-18
PT2436375T (pt) 2019-05-24
US20080153879A1 (en) 2008-06-26
EP1635783A2 (en) 2006-03-22
US20120270903A1 (en) 2012-10-25
US20150283123A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
BRPI0406674A (pt) Composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de um aditivo farmaceuticamente aceitável, método para o tratamento ou prevenção de dor aguda ou crÈnica, dispositivo para pulverização, e, processo para preparar uma composição
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
MXPA05002883A (es) Formas de dosis y terapias relacionadas.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BR0315337A (pt) Composto, formulação farmacêutica, e, método para tratar câncer
BR0306919A (pt) Métodos para reduzir ou suprimir a efetividade adversa da terapia de l-dopa e/ou do agonista da dopamina, e para tratamento moderado de l-dopa, composição para tratamento moderado de l-dopa, método para tratar doença de parkinson e/ou complicações motoras de l-dopa, composição para o tratamento da doença de parkinson, e, métodos para prolongar o tratamento eficaz da doença de parkinson, e para tratar os distúrbios de movimento
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
MX2015017307A (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington.
BR0013478A (pt) Combinação sinergìstica
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
BR112012015499A2 (pt) método de tratamento de fibrilação atrial
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
BR112014015482A8 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
BR0111207A (pt) Combinações de um antagonista receptor de endotelina e um composto antiepiléptico tendo propriedades de alìvio da dor ou analgésicos
BR0012175A (pt) Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
MX2024009444A (es) Métodos de tratamiento para la fibrosis quística
BR112022014861A2 (pt) Métodos de tratamento para deficiência de alfa-1 antittripsina
BRPI0410837A (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma doença ou condição
EA200501166A1 (ru) Составы и способы лечения тромбоцитемии
BR112012020377A2 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BRPI0417123A (pt) formulação de torsemide de liberação prolongada

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 22/12/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2809 DE 05/11/2024 POR TER SIDO INDEVIDA.